Innovation Pharmaceuticals Inc (IPIX)

[NanoEngineer]

I think BK has clearly demonstrated that your argument is not valid.
He has shed some light on the fact that the doses used in pre-clinical studies cannot be easily converted to the doses required in clinical studies to reach efficacy as you originally claimed. Therefore, the fact that the doses used in the pre-clinical studies are different from the doses currently used in the clinical trial is not relevant since they cannot be easily compared with your method.

Do you still claim that Dr Menon was wrong when he mentioned that 200mg/m2 is probably in the efficacy range ?

BigK:

Why are you trying to steer the discussion away from the FACT that the dose used in the preclinical studies were much much greater than the current 359 mg/sq m used in the ninth cohort on the human clinical trial?